If NEU execs are indeed at a biotech investor show in USA then they will be receiving the same message that AHZ received loud and clear last year .... no penny dreadfuls!
So stand by for the one-for-ten consolidation
In addition, we are now a couple of months further on from November and have committment for "only" $1 mill in funding assistance ..... so stand by for the CR shortly after the consolidation, or perhaps a placement.
The way I read this, the message is that for Fragile X and Rett Syndrome there is a need to work through Phase 3 studies (big & expensive) which means we are looking at end of 2017 ... into 2018 ... before all development work finished and risk-free (for prospective buyers) and saleable. .... that's 2 more years!
But I do agree that if the Intrepid study went well then we might see benefits in the share price.
Fingers crossed!
NEU Price at posting:
12.5¢ Sentiment: Hold Disclosure: Held
A personalised tool to help users track selected stocks. Delivering real-time notifications on price updates, announcements, and performance stats on each to help make informed investment decisions.
(20min delay)